查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095658

肽類抗生素市場－2026-2032年全球市場預測

Peptide Antibiotics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胜肽類抗生素市場將成長至 77.1 億美元，複合年成長率為 5.43%。

主要市場統計數據
基準年 2025 53.2億美元
預計年份：2026年 56億美元
預測年份 2032 77.1億美元
複合年成長率 (%) 5.43%

隨著抗生素抗藥性、難治性革蘭氏陰性病菌感染感染以及生物膜相關疾病對傳統抗生素研發帶來日益嚴峻的壓力，胜肽類抗生素作為具有重要戰略意義的感染疾病物再次受到關注。這類抗生素包括天然來源、半合成和人工設計的抗菌胜肽，其作用機轉包括破壞細胞膜、抑制細胞壁合成、免疫調節、標靶干擾細菌生理功能。臨床上已應用的肽類抗生素，例如醣肽、脂肽、多粘菌素和環肽，在醫院感染控制中繼續發揮核心作用，而新一代候選藥物正被最佳化以提高其療效、選擇性、穩定性和安全性。推動這一領域發展的因素包括：迫切的公共衛生需求、合理使用抗菌藥物的要求、胜肽化學的進步以及電腦輔助藥物發現技術的日益普及。肽類抗生素因其作用機制與許多小分子抗生素不同，能夠對抗抗藥性病原體，因此在感染疾病治療、醫院處方集、學術轉化研究和生物製造生態系統中重新引起了人們的關注。

肽類抗生素領域的變革性變化

胜肽類抗生素領域正經歷結構性轉變，從依賴藥物作為「最後手段」轉向精準設計、針對特異性適應症的抗感染解決方案。固相胜肽合成、環化策略、脂化、交聯、偶聯和製劑技術等方面的科學進步正在克服傳統的障礙，例如蛋白水解不穩定性、腎毒性、口服生物生物有效性低和組織滲透性差。同時，抗菌藥物合理使用方案正在重塑臨床應用，優先考慮基於藥敏試驗的用藥、治療藥物監測以及與感染控制的整合。監管部門對抗菌藥物創新的獎勵，以及全球衛生當局發布的優先病原體清單，正引導研究方向轉向多重抗藥性革蘭氏陰性菌、抗藥性金黃色葡萄球菌（MRSA）、萬古黴素抗藥性腸球菌和醫療設備相關感染疾病。這種轉變在製造業領域也十分明顯，品質源自於設計（QbD）方法、雜質分析、可擴展的純化以及內毒素控制正成為胜肽類注射用抗生素的關鍵要素。這些變化共同作用，正將肽類抗生素從小眾的救命療法轉變為對抗抗生素抗藥性的更廣泛平台。

人工智慧對胜肽類抗生素的累積影響

人工智慧透過改進抗菌肽序列的鑑定、設計、篩檢和最佳化，加速了胜肽類抗生素的發現。利用精心整理的胜肽資料庫、基因組資料集、病原體敏感性譜和理化說明訓練的機器學習模型，可以優先篩選出具有預測抗菌活性、溶血性降低、細胞毒性降低和穩定性提高的候選物質。生成式人工智慧和深度學習技術透過提案非天然胺基酸取代、序列基序、環狀骨架和兩性結構（這些結構難以透過傳統的試驗法識別），擴展了化學多樣性。人工智慧驅動的構效關係（SAR）建模有助於研究人員平衡療效與藥物動力學和安全性限制，而In Silico毒性預測可以降低後期研發階段的失敗率。除了藥物發現之外，人工智慧還透過抗藥性監測、診斷決策支援、劑量最佳化和醫院感染趨勢分析，支持抗菌藥物的合理使用。這些協同作用正在推動肽類抗生素的研發進程加快，數據驅動，將分子設計與臨床需求聯繫起來，但嚴格的實驗室檢驗、可重複性、監管透明度和高品質資料集對於負責任的部署仍然至關重要。

肽類抗生素的關鍵區域見解

由於亞太地區感染疾病負擔沉重、醫院基礎設施不斷完善、學名藥生產基礎雄厚以及生物技術投資不斷成長，該地區在肽類抗生素領域的影響力日益增強。中國、印度、日本、韓國和澳洲透過整合活性成分生產、臨床研究、抗菌藥物抗藥性監測和先進的胜肽類科學技術，為該地區的發展做出了貢獻。在歐洲，針對抗菌藥物抗藥性的政策環境高度規範，擁有完善的合理用藥指南、跨境監測和合作研究舉措，支持循證使用第一線抗生素。北美受益於成熟的感染疾病研究網路、醫院合理用藥基礎設施、學術創新以及支持開發用於治療嚴重和危及生命的感染疾病的抗菌藥物的監管途徑。該地區還在三級醫療機構廣泛採用快速診斷和治療監測技術，從而支持複雜肽類抗生素的合理使用。在拉丁美洲，醫療保健服務可近性、監測體係不均衡以及醫院獲得性抗生素抗藥性感染等挑戰依然存在，但巴西和墨西哥正在不斷加強其檢測能力、公共衛生監測和本地臨床專業知識。非洲的情況獨具特色，其特點是感染疾病率高、診斷基礎設施差異大、供應鏈受限以及對價格合理、品質有保證的抗生素的需求。改善檢測網路、加強抗菌藥物抗藥性報告以及保障基本藥物的可及性，對於未來引入肽類抗生素至關重要。在中東，感染預防、重症監護能力和抗菌藥物管治是優先事項，尤其是在高所得醫療體系中，這些系統致力於減少醫院感染並改善處方藥清單管理。

影響胜肽類抗生素的關鍵群體見解

儘管北約成員國並非醫療衛生集團，但它們日益認知到抗菌素抗藥性是一個安全和緊急準備的問題，尤其因為抗藥性感染疾病會影響軍醫、創傷護理、野戰醫院和全球衛生韌性。七國集團成員國在資助感染疾病研究和開發、制定監管標準、支持抗生素研發的「推拉式」獎勵以及在醫院推廣合理使用抗菌藥物方面發揮著主導作用。歐盟為抗菌素抗藥性監測、合理使用抗菌藥物、感染預防和研究合作提供了最主導的框架之一，鼓勵循證用藥，並將藥物作為最後的手段進行嚴格監測。金磚國家擁有龐大的患者群體、不斷擴大的藥品生產能力、日益增強的生物技術能力以及嚴峻的抗菌素抗藥性挑戰，因此在肽類抗生素的需求側臨床需求和供應側創新方面都發揮著核心作用。東南亞國協正在加強其抗菌素抗藥性計畫、檢查室和提高醫療品質的努力，從而為在嚴重感染疾病中合理使用胜肽類抗生素創造一個更協調的環境。由於東南亞國協醫療保健體系的差異，胜肽類抗生素的使用受到經濟負擔、醫院可近性、診斷能力和採購政策的影響。海灣合作理事會（GCC）國家受益於大規模的醫療保健投資、先進的三級醫療設施以及不斷擴大的合理用藥項目，正根據區域抗藥性模式，支持在重症監護、移植醫學和複雜感染疾病的治療中使用肽類抗生素。

主要國家肽類抗生素發展趨勢

美國是胜肽類抗生素創新領域的領先中心，這得益於其在感染疾病研究、先進的醫院抗生素使用方案、快速診斷技術以及針對嚴重細菌感染疾病的監管機制方面的實力。中國正在拓展其生物技術能力、醫院基礎設施、抗生素抗藥性監測和國內胜肽研究，而德國的優勢在於臨床研究、醫院品管體係以及製藥生產方面的專業知識。日本在胜肽類科學、高品質的臨床護理和嚴格的監管標準方面擁有深厚的專業知識，為最佳化抗菌肽的創新提供了支持。印度擁有大規模的生產能力，但感染疾病負擔沉重，因此需要更嚴格的抗生素使用控制。同時，英國擁有先進的抗生素使用控制政策、全國性的監測系統以及強大的感染疾病學術實力。法國繼續致力於抗生素使用控制、感染預防和轉化研究，而加拿大則強調監測、使用控制和公平獲取，重點是醫院中基於循證醫學的先進感染疾病物的使用。澳洲透過健全的監測系統、管理方案以及在社區公共衛生領域的領導角色做出貢獻。巴西在臨床需求、研究能力和公共衛生監測方面都面臨著巨大的挑戰，同時也努力解決區域間在藥物取得和檢測基礎設施方面的差距。義大利和西班牙支持以胜肽類抗生素作為最後的治療手段，並遵循抗菌藥物管理原則，同時致力於應對醫療相關感染和抗藥性革蘭氏陰性菌帶來的沉重負擔。墨西哥，尤其是在都市區醫療機構中，日益需要加強抗菌藥物管治、擴大診斷範圍並採取感染控制措施。韓國正大力推動生物製藥研發、感染控制和精準醫療基礎設施建設，並有望在下一代胜肽類抗生素的研發和推廣中發揮關鍵作用。俄羅斯在抗藥性感染疾病方面存在巨大的臨床需求，擁有龐大的醫院網路，並持續需要強力的監測和品質保證的藥物獲取途徑。

為行業領導者提供的實用建議

產業領導者應優先發展針對明確未滿足臨床需求的胜肽類抗生素項目，特別是針對多重抗藥性革蘭氏陰性病菌感染、抗藥性革蘭氏陽性病菌感染感染、生物膜相關疾病以及需要根治性治療的感染疾病。研發策略應儘早考慮合理使用抗菌藥物、病原體特異性定位、伴隨診斷以及藥物動力學和動態最佳化。各機構應投資人工智慧驅動的胜肽藥物發現，同時維持嚴格的實驗檢驗、透明的模型管治和高品質的生物資料集。生產團隊應提升胜肽類注射劑可擴展的合成、純化、雜質控制、無菌保證和供應鏈韌性。臨床和商業團隊應儘早與感染疾病專家、微生物實驗室、醫院藥劑師和抗菌藥物使用委員會合作，使實證醫學證據與臨床實踐中的處方要求保持一致。與學術實驗室、公共衛生網路和合約開發專家建立合作關係可以加速轉化研究的進展。同時，監管計畫必須解決抗藥性風險、安全監測以及上市後合理使用義務等問題。最重要的是，成功取決於創新與負責任的用藥途徑之間的平衡，確保胜肽類抗生素繼續作為對抗抗菌素抗藥性的有效工具至關重要。

肽類抗生素分析的調查方法

分析胜肽類抗生素的調查方法應結合二手資料研究、專家一手檢驗和結構化資料的檢驗。可靠的二級資訊來源包括同行評審的感染疾病期刊、抗菌藥物抗藥性監測報告、監管指南、醫院合理用藥出版刊物、臨床試驗註冊庫、藥典和公共衛生機構文件。一手資訊應從感染疾病醫生、臨床微生物學家、醫院藥劑師、胜肽類化學家、監管專家和生產專家收集，並檢驗其臨床相關性、引入障礙、安全性考量和研發重點。資料應從作用機制、胜肽類分類、目標病原體、給藥途徑、製劑方法、抗藥性模式、監管背景以及當地醫療保健系統的發展等方面進行分析。檢驗應協調科學文獻、臨床實務證據、採購趨勢和政策發展，而不依賴檢驗的假設。品管應包括資訊來源的可靠性評估、資料有效性、術語標準化、去除重複資料以及偏差檢驗。該調查方法支持對肽類抗生素進行檢驗和基於證據的理解，同時避免投機性的市場規模估計和沒有根據的預測。

結論：胜肽類抗生素的策略性展望

肽類抗生素在全球應對抗菌素抗藥性方面發揮著至關重要的作用。它們作用機制多樣，在嚴重感染疾病中具有重要的臨床意義，並且與現代胜肽工程技術親和性，使其成為感染疾病物創新的重點。儘管化學、製劑、診斷、合理用藥管理和人工智慧方面的突破性進展正在拓展胜肽類抗生素的應用前景，但區域和國家在監測、藥物取得、醫療基礎設施和政策方面的差異仍然影響著胜肽類抗生素的推廣應用。能夠將科學創新與臨床效用、監管嚴格性、可生產性和合理用藥相結合的相關人員將取得最大的成功。隨著抗藥性病原體持續挑戰醫療衛生系統，胜肽類抗生素在目前的治療方案和下一代抗菌藥物的研發中仍將發揮不可或缺的作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 胜肽類抗生素市場：依藥物類別分類

  • 醣肽
    • 萬古黴素類抗生素
    • Teicoplanin抗生素
    • 達伐萬星類抗生素
    • 奧利他班星類抗生素
    • 特拉萬星類抗生素
  • 脂肽
    • Daptomycin抗生素
    • 基於表面活性素的抗生素
  • 多粘菌素
    • 粘菌素類抗生素
    • 多粘菌素B類抗生素
  • 環肽
    • 桿菌肽類抗生素
    • 基於短桿菌肽的抗生素
  • 抗菌胜肽
    • 卡他利啶肽
    • 防禦素胜肽
    • 基於天蠶素的胜肽

第8章：胜肽類抗生素市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服
  • 外用

第9章：胜肽類抗生素市場：依劑型分類

  • 注射藥物
    • 凍乾粉
    • 解決方案
  • 粉末
  • 外用製劑
    • 奶油
    • 軟膏

第10章：胜肽類抗生素市場：依來源分類

  • 天然來源
    • 微生物來源
    • 植物來源
    • 動物源性
  • 合成

第11章：胜肽類抗生素市場：依作用機制分類

  • 細胞壁合成抑制劑
  • 細胞膜破壞劑
  • 蛋白質合成抑制劑
  • 核酸合成抑制劑
  • 免疫調節胜肽類抗生素

第12章 胜肽類抗生素市場：依目標病原體組分類

  • 革蘭氏陽性菌
  • 革蘭氏陰性菌
  • 多重抗藥性病原體
  • 厭氧菌
  • 非典型細菌
  • 分枝桿菌
  • 真菌病原體
  • 多微生物感染疾病

第13章：胜肽類抗生素市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 胜肽類抗生素市場：依適應症分類

  • 皮膚和軟組織感染疾病
  • 血液感染疾病
  • 呼吸道感染疾病
  • 尿道感染
  • 胃腸道感染疾病
  • 骨骼和關節感染疾病
  • 院內感染

第15章：胜肽類抗生素市場：依最終用途分類

  • 診所
  • 醫院
  • 動物診所
  • 學術研究機構

第16章 胜肽類抗生素市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第17章 胜肽類抗生素市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第18章 胜肽類抗生素市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 澳洲
  • 巴西
  • 義大利
  • 墨西哥
  • 韓國
  • 俄羅斯
  • 西班牙

第19章 競爭情勢

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第20章：公司簡介

  • AbbVie Inc.
  • Alkem Laboratories Limited
  • Amicrobe, Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biological E. Limited
  • Biolytx Pharmaceuticals Corp.
  • Centauri Therapeutics Limited
  • Cipla Limited
  • Concord Biotech Limited
  • Cumberland Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Limited
  • Fresenius SE & Co. KGaA
  • Gland Pharma Limited
  • Glenmark Pharmaceuticals Limited
  • Hetero Labs Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Livzon Pharmaceutical Group Inc.
  • Lupin Limited
  • Lytix Biopharma AS
  • Melinta Therapeutics, LLC
  • Merck & Co., Inc.
  • Peptilogics, Inc.
  • Pfizer Inc.
  • Sandoz Group AG
  • Spero Therapeutics, Inc.
  • Spexis AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xellia Pharmaceuticals ApS
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
Product Code: MRR-205091A88A0F

The Peptide Antibiotics Market is projected to grow by USD 7.71 billion at a CAGR of 5.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.32 billion
Estimated Year [2026] USD 5.60 billion
Forecast Year [2032] USD 7.71 billion
CAGR (%) 5.43%

Peptide antibiotics are re-emerging as strategically important anti-infective agents as antimicrobial resistance, difficult-to-treat Gram-negative infections, and biofilm-associated diseases intensify pressure on conventional antibiotic pipelines. This class includes naturally derived, semisynthetic, and engineered antimicrobial peptides that act through membrane disruption, cell-wall synthesis inhibition, immunomodulation, and targeted interference with bacterial physiology. Clinically established peptide antibiotics, including glycopeptides, lipopeptides, polymyxins, and cyclic peptides, remain central to hospital infection management, while next-generation candidates are being optimized for improved potency, selectivity, stability, and safety. The field is shaped by urgent public health needs, antimicrobial stewardship requirements, advances in peptide chemistry, and growing use of computational drug design. Because peptide antibiotics can address resistant pathogens through mechanisms distinct from many small-molecule antibiotics, they are drawing renewed attention across infectious disease therapeutics, hospital formularies, academic translational research, and biomanufacturing ecosystems.

Transformative Shifts in the Peptide Antibiotics Landscape

The peptide antibiotics landscape is undergoing a structural shift from reliance on legacy last-resort drugs toward precision-designed, indication-specific anti-infective solutions. Scientific progress in solid-phase peptide synthesis, cyclization strategies, lipidation, stapling, conjugation, and formulation technologies is helping overcome historical barriers such as proteolytic instability, nephrotoxicity, poor oral bioavailability, and limited tissue penetration. At the same time, antimicrobial stewardship programs are reshaping clinical utilization by prioritizing susceptibility-guided use, therapeutic drug monitoring, and infection-control integration. Regulatory incentives for antibacterial innovation, coupled with priority pathogen lists published by global health authorities, are directing research toward multidrug-resistant Gram-negative bacteria, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and device-associated infections. The shift is also visible in manufacturing, where quality-by-design approaches, impurity profiling, scalable purification, and endotoxin control are becoming essential for peptide-based injectable antibiotics. Together, these changes are transforming peptide antibiotics from niche rescue therapies into a broader platform for combating antimicrobial resistance.

Cumulative Impact of Artificial Intelligence on Peptide Antibiotics

Artificial intelligence is accelerating peptide antibiotic discovery by improving the identification, design, screening, and optimization of antimicrobial peptide sequences. Machine learning models trained on curated peptide databases, genomic datasets, pathogen susceptibility profiles, and physicochemical descriptors can prioritize candidates with predicted antibacterial activity, reduced hemolysis, lower cytotoxicity, and improved stability. Generative AI and deep learning approaches are expanding chemical diversity by proposing non-natural amino acid substitutions, sequence motifs, cyclic scaffolds, and amphipathic architectures that would be difficult to identify through conventional trial-and-error methods. AI-supported structure-activity relationship modeling is also helping researchers balance potency with pharmacokinetic and safety constraints, while in silico toxicity prediction can reduce late-stage attrition. Beyond discovery, artificial intelligence supports antimicrobial stewardship through resistance surveillance, diagnostic decision support, dose optimization, and hospital infection trend analysis. The cumulative impact is a faster, more data-driven peptide antibiotic pipeline that links molecular design with clinical need, although rigorous wet-lab validation, reproducibility, regulatory transparency, and high-quality datasets remain essential for responsible deployment.

Key Regional Insights Across Peptide Antibiotics

Asia-Pacific is increasingly influential in peptide antibiotics due to its large infectious disease burden, expanding hospital infrastructure, strong generic pharmaceutical manufacturing base, and growing investment in biotechnology. China, India, Japan, South Korea, and Australia contribute through a mix of active pharmaceutical ingredient production, clinical research, antimicrobial resistance surveillance, and advanced peptide science. Europe maintains a highly structured policy environment for antimicrobial resistance, with strong stewardship guidance, cross-border surveillance, and coordinated research initiatives supporting evidence-based use of last-line antibiotics. North America benefits from established infectious disease research networks, hospital stewardship infrastructure, academic innovation, and regulatory pathways that support antibacterial development for serious and life-threatening infections. The region also shows strong adoption of rapid diagnostics and therapeutic drug monitoring in tertiary care settings, which supports appropriate use of complex peptide antibiotics. Latin America faces persistent challenges related to healthcare access, surveillance heterogeneity, and resistant hospital-acquired infections, yet Brazil and Mexico continue to strengthen laboratory capacity, public health monitoring, and local clinical expertise. Africa presents a distinct landscape shaped by infectious disease prevalence, variable diagnostic infrastructure, supply-chain constraints, and the need for affordable, quality-assured antibiotics; regional initiatives to improve laboratory networks, antimicrobial resistance reporting, and essential medicine access are critical to future peptide antibiotic adoption. The Middle East is prioritizing infection prevention, intensive care capacity, and antimicrobial governance, particularly in high-income health systems seeking to reduce hospital-associated infections and improve formulary control.

Key Group Insights Influencing Peptide Antibiotics

NATO members, while not a healthcare bloc, increasingly recognize antimicrobial resistance as a security and readiness concern, particularly because resistant infections can affect military medicine, trauma care, field hospitals, and global health resilience. G7 members play a leading role in funding infectious disease research, setting regulatory standards, supporting push-and-pull incentives for antibiotic development, and advancing hospital stewardship models. The European Union provides one of the most coordinated frameworks for antimicrobial resistance surveillance, antibiotic stewardship, infection prevention, and research collaboration, encouraging evidence-based use and careful monitoring of last-line agents. BRICS countries combine large patient populations, expanding pharmaceutical manufacturing, rising biotechnology capacity, and significant antimicrobial resistance challenges, making them central to both demand-side clinical needs and supply-side innovation in peptide antibiotics. ASEAN countries are strengthening antimicrobial resistance action plans, laboratory surveillance, and healthcare quality initiatives, creating a more coordinated environment for the responsible use of peptide antibiotics in severe infections. Diverse healthcare systems across ASEAN mean adoption is shaped by affordability, hospital access, diagnostic capability, and procurement policy. The GCC benefits from substantial healthcare investment, advanced tertiary hospitals, and growing stewardship programs, supporting the use of peptide antibiotics in intensive care, transplant medicine, and complex infection management when guided by local resistance patterns.

Key Country Insights Shaping Peptide Antibiotics

The United States is a major center for peptide antibiotic innovation, supported by infectious disease research, advanced hospital stewardship, rapid diagnostics, and regulatory mechanisms for serious bacterial infections. China is expanding biotechnology capabilities, hospital infrastructure, antimicrobial resistance monitoring, and domestic peptide research, while Germany's strengths include clinical research, hospital quality systems, and pharmaceutical manufacturing expertise. Japan has deep expertise in peptide science, high-quality clinical care, and stringent regulatory standards, supporting innovation in optimized antimicrobial peptides. India combines major manufacturing capacity with a high infectious disease burden and the need for tighter antibiotic stewardship, while the United Kingdom has advanced antimicrobial stewardship policies, national surveillance systems, and strong academic infectious disease expertise. France continues to focus on antibiotic stewardship, infection prevention, and translational research, while Canada emphasizes surveillance, stewardship, and equitable access, with hospitals focusing on evidence-based use of advanced anti-infectives. Australia contributes through strong surveillance systems, stewardship programs, and regional public health leadership. Brazil combines substantial clinical need with growing research capacity and public health surveillance, while also addressing regional disparities in access and laboratory infrastructure. Italy and Spain manage notable burdens of healthcare-associated infections and resistant Gram-negative pathogens, supporting stewardship-guided use of last-line peptide antibiotics. Mexico faces rising demand for strengthened antimicrobial governance, improved diagnostic coverage, and hospital infection control, particularly in urban care centers. South Korea is advancing biopharmaceutical research, hospital infection control, and precision medicine infrastructure, positioning it as an important participant in next-generation peptide antibiotic development and adoption. Russia has significant clinical demand related to resistant infections and a large hospital network, with ongoing need for robust surveillance and quality-assured access.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize peptide antibiotic programs that address clearly defined unmet clinical needs, especially multidrug-resistant Gram-negative infections, resistant Gram-positive infections, biofilm-associated disease, and infections requiring last-line therapy. Development strategies should integrate early antimicrobial stewardship considerations, pathogen-specific positioning, companion diagnostics, and pharmacokinetic/pharmacodynamic optimization. Organizations should invest in AI-enabled peptide discovery while maintaining strong experimental validation, transparent model governance, and high-quality biological datasets. Manufacturing teams should strengthen scalable synthesis, purification, impurity control, sterility assurance, and supply-chain resilience for peptide-based injectables. Clinical and commercial teams should engage infectious disease specialists, microbiology laboratories, hospital pharmacists, and stewardship committees early to align evidence generation with real-world prescribing requirements. Partnerships with academic laboratories, public health networks, and contract development specialists can accelerate translational progress, while regulatory planning should address resistance risk, safety monitoring, and post-approval stewardship obligations. Above all, success depends on balancing innovation with responsible access, ensuring peptide antibiotics remain effective tools against antimicrobial resistance.

Research Methodology for Peptide Antibiotics Analysis

The research methodology for analyzing peptide antibiotics should combine secondary research, primary expert validation, and structured data triangulation. Reliable secondary sources include peer-reviewed infectious disease journals, antimicrobial resistance surveillance reports, regulatory guidance, hospital stewardship publications, clinical trial registries, pharmacopeial references, and public health agency documents. Primary inputs should be gathered from infectious disease clinicians, clinical microbiologists, hospital pharmacists, peptide chemists, regulatory specialists, and manufacturing experts to validate clinical relevance, adoption barriers, safety considerations, and development priorities. Data should be reviewed across mechanisms of action, peptide classes, target pathogens, routes of administration, formulation approaches, resistance patterns, regulatory status, and regional healthcare readiness. Triangulation should reconcile scientific literature, clinical practice evidence, procurement dynamics, and policy developments without relying on unverified assumptions. Quality controls should include source credibility assessment, date relevance, terminology normalization, duplicate removal, and review for bias. This methodology supports a verified, evidence-led understanding of peptide antibiotics while avoiding speculative market sizing or unsupported forecasting.

Conclusion: Strategic Outlook for Peptide Antibiotics

Peptide antibiotics occupy a critical position in the global response to antimicrobial resistance. Their diverse mechanisms, clinical relevance in severe infections, and compatibility with modern peptide engineering make them an important focus for anti-infective innovation. Transformative advances in chemistry, formulation, diagnostics, stewardship, and artificial intelligence are expanding what is possible, while regional and country-level differences in surveillance, access, healthcare infrastructure, and policy continue to shape adoption. The most successful stakeholders will be those that align scientific innovation with clinical utility, regulatory rigor, manufacturability, and responsible use. As resistant pathogens continue to challenge healthcare systems, peptide antibiotics are set to remain essential in both current treatment protocols and the next generation of antibacterial discovery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Peptide Antibiotics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Glycopeptides
    • 7.2.1. Vancomycin-Based Antibiotics
    • 7.2.2. Teicoplanin-Based Antibiotics
    • 7.2.3. Dalbavancin-Based Antibiotics
    • 7.2.4. Oritavancin-Based Antibiotics
    • 7.2.5. Telavancin-Based Antibiotics
  • 7.3. Lipopeptides
    • 7.3.1. Daptomycin-Based Antibiotics
    • 7.3.2. Surfactin-Based Antibiotics
  • 7.4. Polymyxins
    • 7.4.1. Colistin-Based Antibiotics
    • 7.4.2. Polymyxin B Antibiotics
  • 7.5. Cyclic Peptides
    • 7.5.1. Bacitracin-Based Antibiotics
    • 7.5.2. Gramicidin-Based Antibiotics
  • 7.6. Antimicrobial Peptides
    • 7.6.1. Cathelicidin-Based Peptides
    • 7.6.2. Defensin-Based Peptides
    • 7.6.3. Cecropin-Based Peptides

8. Peptide Antibiotics Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intravenous
  • 8.4. Oral
  • 8.5. Topical

9. Peptide Antibiotics Market, by Formulation

  • 9.1. Introduction
  • 9.2. Injectable
    • 9.2.1. Lyophilized Powder
    • 9.2.2. Solution
  • 9.3. Powder
  • 9.4. Topical Formulation
    • 9.4.1. Cream
    • 9.4.2. Ointment

10. Peptide Antibiotics Market, by Source

  • 10.1. Introduction
  • 10.2. Natural
    • 10.2.1. Microbial-Derived
    • 10.2.2. Plant-Derived
    • 10.2.3. Animal-Derived
  • 10.3. Synthetic

11. Peptide Antibiotics Market, by Mechanism Of Action

  • 11.1. Introduction
  • 11.2. Cell Wall Synthesis Inhibitors
  • 11.3. Cell Membrane Disruptors
  • 11.4. Protein Synthesis Inhibitors
  • 11.5. Nucleic Acid Synthesis Inhibitors
  • 11.6. Immunomodulatory Peptide Antibiotics

12. Peptide Antibiotics Market, by Target Pathogen Group

  • 12.1. Introduction
  • 12.2. Gram-Positive Bacteria
  • 12.3. Gram-Negative Bacteria
  • 12.4. Multidrug-Resistant Pathogens
  • 12.5. Anaerobic Bacteria
  • 12.6. Atypical Bacteria
  • 12.7. Mycobacteria
  • 12.8. Fungal Pathogens
  • 12.9. Polymicrobial Infections

13. Peptide Antibiotics Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacy
  • 13.3. Online Pharmacy
  • 13.4. Retail Pharmacy

14. Peptide Antibiotics Market, by Indication

  • 14.1. Introduction
  • 14.2. Skin & Soft Tissue Infections
  • 14.3. Bloodstream Infections
  • 14.4. Respiratory Tract Infections
  • 14.5. Urinary Tract Infections
  • 14.6. Gastrointestinal Infections
  • 14.7. Bone & Joint Infections
  • 14.8. Hospital-Acquired Infections

15. Peptide Antibiotics Market, by End Use

  • 15.1. Introduction
  • 15.2. Clinics
  • 15.3. Hospitals
  • 15.4. Veterinary Clinics
  • 15.5. Academic & Research Institutes

16. Peptide Antibiotics Market, by Region

  • 16.1. Asia-Pacific
  • 16.2. Europe
  • 16.3. North America
  • 16.4. Latin America
  • 16.5. Africa
  • 16.6. Middle East

17. Peptide Antibiotics Market, by Group

  • 17.1. NATO
  • 17.2. G7
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. ASEAN
  • 17.6. GCC

18. Peptide Antibiotics Market, by Country

  • 18.1. United States
  • 18.2. China
  • 18.3. Germany
  • 18.4. Japan
  • 18.5. India
  • 18.6. United Kingdom
  • 18.7. France
  • 18.8. Canada
  • 18.9. Australia
  • 18.10. Brazil
  • 18.11. Italy
  • 18.12. Mexico
  • 18.13. South Korea
  • 18.14. Russia
  • 18.15. Spain

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2025
  • 19.2. FPNV Positioning Matrix, 2025
  • 19.3. Market Concentration Analysis, 2025
    • 19.3.1. Concentration Ratio (CR)
    • 19.3.2. Herfindahl Hirschman Index (HHI)
  • 19.4. Recent Developments & Impact Analysis, 2025
  • 19.5. Product Portfolio Analysis, 2025
  • 19.6. Benchmarking Analysis, 2025

20. Company Profiles

  • 20.1. AbbVie Inc.
  • 20.2. Alkem Laboratories Limited
  • 20.3. Amicrobe, Inc.
  • 20.4. Amneal Pharmaceuticals, Inc.
  • 20.5. ANI Pharmaceuticals, Inc.
  • 20.6. Aurobindo Pharma Limited
  • 20.7. Baxter International Inc.
  • 20.8. Biological E. Limited
  • 20.9. Biolytx Pharmaceuticals Corp.
  • 20.10. Centauri Therapeutics Limited
  • 20.11. Cipla Limited
  • 20.12. Concord Biotech Limited
  • 20.13. Cumberland Pharmaceuticals Inc.
  • 20.14. Dr. Reddy's Laboratories Limited
  • 20.15. Fresenius SE & Co. KGaA
  • 20.16. Gland Pharma Limited
  • 20.17. Glenmark Pharmaceuticals Limited
  • 20.18. Hetero Labs Limited
  • 20.19. Hikma Pharmaceuticals PLC
  • 20.20. Intas Pharmaceuticals Limited
  • 20.21. Livzon Pharmaceutical Group Inc.
  • 20.22. Lupin Limited
  • 20.23. Lytix Biopharma AS
  • 20.24. Melinta Therapeutics, LLC
  • 20.25. Merck & Co., Inc.
  • 20.26. Peptilogics, Inc.
  • 20.27. Pfizer Inc.
  • 20.28. Sandoz Group AG
  • 20.29. Spero Therapeutics, Inc.
  • 20.30. Spexis AG
  • 20.31. Sun Pharmaceutical Industries Limited
  • 20.32. Teva Pharmaceutical Industries Ltd.
  • 20.33. Viatris Inc.
  • 20.34. Xellia Pharmaceuticals ApS
  • 20.35. Zhejiang Hisun Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE ANTIBIOTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PEPTIDE ANTIBIOTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 31. GLOBAL PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLYCOPEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLYCOPEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLYCOPEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VANCOMYCIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VANCOMYCIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VANCOMYCIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TEICOPLANIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TEICOPLANIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TEICOPLANIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DALBAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DALBAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DALBAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORITAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORITAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORITAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TELAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TELAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TELAVANCIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIPOPEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIPOPEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIPOPEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DAPTOMYCIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DAPTOMYCIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DAPTOMYCIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SURFACTIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SURFACTIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SURFACTIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POLYMYXINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POLYMYXINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYMYXINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLISTIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLISTIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLISTIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POLYMYXIN B ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POLYMYXIN B ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POLYMYXIN B ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BACITRACIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BACITRACIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BACITRACIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GRAMICIDIN-BASED ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GRAMICIDIN-BASED ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GRAMICIDIN-BASED ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CATHELICIDIN-BASED PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CATHELICIDIN-BASED PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CATHELICIDIN-BASED PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DEFENSIN-BASED PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DEFENSIN-BASED PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DEFENSIN-BASED PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CECROPIN-BASED PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CECROPIN-BASED PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CECROPIN-BASED PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TOPICAL FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TOPICAL FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TOPICAL FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OINTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OINTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NATURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NATURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NATURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MICROBIAL-DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MICROBIAL-DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MICROBIAL-DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLANT-DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PLANT-DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLANT-DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL-DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL-DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL-DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL WALL SYNTHESIS INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL WALL SYNTHESIS INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL WALL SYNTHESIS INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL MEMBRANE DISRUPTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL MEMBRANE DISRUPTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL MEMBRANE DISRUPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID SYNTHESIS INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NUCLEIC ACID SYNTHESIS INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NUCLEIC ACID SYNTHESIS INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNOMODULATORY PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNOMODULATORY PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNOMODULATORY PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GRAM-POSITIVE BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GRAM-POSITIVE BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GRAM-POSITIVE BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GRAM-NEGATIVE BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GRAM-NEGATIVE BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GRAM-NEGATIVE BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MULTIDRUG-RESISTANT PATHOGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MULTIDRUG-RESISTANT PATHOGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MULTIDRUG-RESISTANT PATHOGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANAEROBIC BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANAEROBIC BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ANAEROBIC BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ATYPICAL BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ATYPICAL BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ATYPICAL BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MYCOBACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MYCOBACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MYCOBACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL POLYMICROBIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL POLYMICROBIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL POLYMICROBIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL SKIN & SOFT TISSUE INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL SKIN & SOFT TISSUE INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL SKIN & SOFT TISSUE INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL RESPIRATORY TRACT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL RESPIRATORY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL RESPIRATORY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BONE & JOINT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BONE & JOINT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BONE & JOINT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL HOSPITAL-ACQUIRED INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL HOSPITAL-ACQUIRED INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HOSPITAL-ACQUIRED INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 307. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 310. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 311. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 312. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 314. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 315. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 317. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 318. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 319. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 320. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 321. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 322. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 325. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 326. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 328. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 329. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 330. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 331. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 332. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 333. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 334. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 335. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 336. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 337. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 338. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 339. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 340. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 341. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 342. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 343. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXINS, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 354. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 355. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 356. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 357. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 358. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY TARGET PATHOGEN GROUP, 2018-2032 (USD MILLION)
  • TABLE 359. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 360. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 361. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2